Gallium-68 PSMA

Drug Profile

Gallium-68 PSMA

Alternative Names: (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)PSMA-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-PSMA; 68Ga-PSMA HBED-CC; 68Ga-PSMA HBED-PET/CT; 68Ga-PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-PSMA-11; 68Ga-PSMA-ligand; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC; Ga-68 labeled PSMA-11 PET; Ga-68-PSMA-11; Gallium-68 labeled PSMA-11; ProstaMedix; PSMA-HBED-CC GA-68

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RadioMedix
  • Developer Chang Gung Memorial Hospital; Friedrich-Alexander-University Erlangen-Nuremberg; German Cancer Research Center; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Jewish General Hospital; Medical University of Vienna; Princess Alexandra Hospital; Sir Charles Gairdner Hospital; University Medical Center Groningen; University of California at San Francisco; University of Zurich
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Adenocarcinoma; Renal cell carcinoma

Most Recent Events

  • 27 Nov 2017 University of California initiates enrolment in a phase III trial for Prostrate cancer (Diagnosis) in USA (NCT03353740)
  • 09 Oct 2017 Phase-I/II clinical trials in Prostate cancer (Diagnosis, Newly diagnosed) in Germany (IV) (NCT03362359)
  • 01 Oct 2017 Phase-III clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT03353740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top